Good response, Dave. I am expecting more than j
Post# of 30029
I am expecting more than just Lympro data next week. GC owes us that much after several months of stringing us along with final Lympro numbers.
Hopefully I am not expecting too much, but I know more Lympro data, without proof of revenue, will not move the share price. Unless the spec/sen numbers are high 90s. That might be a different story I suppose.